Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Trial Profile

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs Evinacumab (Primary) ; Evinacumab (Primary)
  • Indications Metabolic disorders
  • Focus Adverse reactions; First in man
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results for Group A (n=83), published in the New England Journal of Medicine
    • 24 May 2017 Results published in the New England Journal of Medicine, according to a Regeneron Pharmaceuticals media release.
    • 16 Nov 2016 Results assessing safety and efficacy of Evinacumab, presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top